Skip to main content
2025 AANS Annual Scientific Meeting Main banner
Back

    Michael Lim, MD

    Professor and Chair of Neurosurgery
    Stanford University School of Medicine

    Dr. Michael Lim is a Professor and Chair of Neurosurgery at Stanford University. Dr. Lim obtained his MD from the Johns Hopkins University School of Medicine. He then completed his residency in Neurosurgery at Stanford University Hospital and went on to become a Professor of Neurosurgery, Oncology and Radiation Oncology at Johns Hopkins before returning to Stanford as Chair. Dr. Lim’s surgical interest is in both benign and malignant brain tumors, with a particular interest in gliomas (including ependymoma), meningioma, pituitary tumors and skull base tumors. He has extensive experience in new and innovative neurosurgical techniques including image guided surgery, microsurgery, minimally invasive procedures and endoscopic surgery.

    Dr. Lim’s primary research interest is developing immune-based therapies against brain tumors. His research laboratory is focused on understanding the mechanisms of immune evasion by primary brain tumors. Findings from his laboratory are directed towards translation to novel therapies against brain tumors. In addition to running a laboratory, he currently serves as the principal investigator of several large brain tumor immunotherapy clinical trials based on findings from his laboratory.

    Disclosure(s): Accuray: Research Grant (Ongoing); Arbor: Research Grant (Ongoing); Biohaven: Consultant (Ongoing), Research Grant (Ongoing); BMS: Consultant (Ongoing), Research Grant (Ongoing); Century Therapeutics: Consultant (Ongoing); CraniUs: Consultant (Ongoing); Egret Therapeutics: Ownership or Partnership (Ongoing), Ownership or Partnership (Ongoing), Stock Shareholder (excluding mutual funds) (Ongoing); Hemispherian: Consultant (Ongoing); InCando: Consultant (Ongoing); InCephalo: Consultant (Ongoing), Research Grant (Ongoing); InSightec: Consultant (Ongoing), Research Grant (Ongoing); MediFlix: Consultant (Ongoing); Merck: Consultant (Ongoing); Novocure, Inc.: Consultant (Ongoing), Research Grant (Ongoing); Noxxon: Consultant (Ongoing); Pyarmid Bio: Stock Shareholder (excluding mutual funds) (Ongoing); Sanianoia: Consultant (Ongoing), Grant/Research Support (Ongoing); VBI: Consultant (Ongoing)

    Presentation(s):